Balance of ischemia and bleeding in selecting antithrombotic regimens

Bimmer E.P.M. Claessen, José P.S. Henriques

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


In the USA, coronary revascularization by percutaneous coronary intervention (PCI) is performed over 1 million times annually. However, PCI has only been associated with improved clinical outcomes when performed for acute coronary syndromes. In patients with stable coronary artery disease, there is an ongoing debate concerning the clinical usefulness of PCI. This chapter provides an overview of pharmacologic treatment strategies to optimize the safety and efficacy of PCI by minimizing the risk of ischemic and bleeding outcomes. Both ischemic and bleeding complications are associated with an increased risk of mortality after PCI. Antithrombotic therapy in PCI is focused on minimizing thrombotic complications while limiting the number of bleeding events. An aspirin loading dose of 325 mg orally or 500 mg intravenously is administered before PCI. Clopidogrel, prasugrel, and ticagrelor inhibit platelet activation by antagonizing the adenosine diphosphate receptor P2Y12.

Original languageEnglish
Title of host publicationInterventional Cardiology
Subtitle of host publicationPrinciples and Practice
Number of pages8
ISBN (Electronic)9781118983652
ISBN (Print)9781118976036
StatePublished - 21 Nov 2016
Externally publishedYes


  • Acute coronary syndromes
  • Acute ischemia
  • Antiplatet therapy
  • Antithrombotic therapy
  • Aspirin
  • Coronary artery disease
  • Coronary revascularization
  • Percutaneous coronary intervention bleeding
  • Pharmacologic treatment strategies


Dive into the research topics of 'Balance of ischemia and bleeding in selecting antithrombotic regimens'. Together they form a unique fingerprint.

Cite this